Twelve versus 30 month dual antiplatelet therapy after percutaneous coronary intervention using national health insurance review & assessment (HIRA) database

被引：0
|
作者：
Lee, K. M. [1 ]
Kim, M. H. [2 ]
Choi, S. Y. [1 ]
Kim, S. J. [2 ]
Jin, C. D. [2 ]
Guo, L. Z. [2 ]
Serebruany, V. L. [3 ]
机构：
[1] Dong A Univ Hosp, Global Clin Trial Ctr, Busan, South Korea
[2] Dong A Univ, Dept Cardiol, Coll Med, Busan, South Korea
[3] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21218 USA
来源：
EUROPEAN HEART JOURNAL | 2016年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P3418
引用
收藏
页码：667 / 667
页数：1
相关论文
共 50 条
  • [1] Stroke rate after twelve versus 30 month dual antiplatelet therapy in percutaneous coronary intervention patients using Korean National Health Insurance Service (NHIS)
    Lee, K. M.
    Kim, M. H.
    Choi, S. Y.
    Kim, S. J.
    Kim, H. B.
    Kang, S. Y.
    Serebruany, V.
    EUROPEAN HEART JOURNAL, 2017, 38 : 836 - 836
  • [2] Triple versus dual antiplatelet therapy of cilostazol or sarpogrelate with aspirin and clopidogrel after percutaneous coronary intervention: a retrospective cohort study using Korean National Health Insurance Claim Database
    Noh, Yoojin
    Lee, Jimin
    Shin, Sooyoung
    Lee, Sukhyang
    PHARMACOTHERAPY, 2015, 35 (11): : E260 - E260
  • [3] Dual antiplatelet therapy after myocardial infarction and percutaneous coronary intervention: analysis of patient adherence using a French health insurance reimbursement database
    Latry, Philippe
    Martin-Latry, Karin
    Lafitte, Marianne
    Peter, Claude
    Couffinhal, Thierry
    EUROINTERVENTION, 2012, 7 (12) : 1413 - 1419
  • [4] Comment on "Dual antiplatelet therapy after myocardial infarction and percutaneous coronary intervention: analysis of patient adherence using a French health insurance reimbursement database"
    Carvalho, Henrique Cyrne
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2012, 31 (7-8) : 543 - 544
  • [5] Antiplatelet Therapy of Cilostazol or Sarpogrelate with Aspirin and Clopidogrel after Percutaneous Coronary Intervention: A Retrospective Cohort Study Using the Korean National Health Insurance Claim Database
    Noh, Yoojin
    Lee, Jimin
    Shin, Sooyoung
    Lim, Hong-Seok
    Bae, Soo Kyung
    Oh, Euichul
    Kim, Grace Juyun
    Kim, Ju Han
    Lee, Sukhyang
    PLOS ONE, 2016, 11 (03):
  • [6] Ticagrelor Monotherapy Following Short Dual Antiplatelet Therapy versus 12-Month Dual Antiplatelet Therapy after Percutaneous Coronary
    Joseph, Meghna
    Krishna, Mrinal Murali
    Ezenna, Chidubem
    Goldsweig, Andrew
    CIRCULATION, 2024, 150
  • [7] Meta-Analysis of One-Month Dual Antiplatelet Therapy Versus Standard Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention
    Mohamed, Mohamed M. G.
    Shaikh, Safia
    Osman, Mohammed
    Kheiri, Babikir
    AMERICAN JOURNAL OF CARDIOLOGY, 2022, 166 : 138 - +
  • [8] Dual antiplatelet therapy after percutaneous coronary intervention: Personalize the duration
    Howard, Travis M.
    Khot, Umesh N.
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 2021, 88 (06) : 325 - 332
  • [9] EFFICACY OF RECTAL DUAL ANTIPLATELET THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION
    Nowrozi, Arian
    Kim, Michael
    Gavrilos, George
    Hadley, Sydney
    Kabbany, Mohammad
    CRITICAL CARE MEDICINE, 2024, 52
  • [10] Navigating the Course of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Review of Guided Approaches
    Ammirabile, Nicola
    Landolina, Davide
    Capodanno, Davide
    CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2023, 16 (12) : E013450
12345